Apremilast, an Oral Phophodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Results From the PALACE 4 Phase 3, Randomized, Controlled Trial

Edwards; Christopher; Wollenhaupt; Jürgen; Adebajo; Adewale; Kivitz; Alan; Bird; Paul; Hu; ChiaChi; Aelion; Jacob A.; Wells; Alvin F.

doi:10.3205/15dgrh225

Apremilast, an Oral Phophodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Results From the PALACE 4 Phase 3, Randomized, Controlled Trial

Identifier:nobleid.org/w1/20260515/3F3A4CD3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3F3A4CD3.svg?ark=w1%2F20260515%2F3F3A4CD3)](https://nobleid.org/work/w1/20260515/3F3A4CD3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Apremilast, an Oral Phophodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Results From the PALACE 4 Phase 3, Randomized, Controlled Trial

Identifier:nobleid.org/w1/20260515/3F3A4CD3

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/3F3A4CD3.svg?ark=w1%2F20260515%2F3F3A4CD3)](https://nobleid.org/work/w1/20260515/3F3A4CD3)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work